Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > REGULATORY
REGULATORY
- PFSB to Initiate Epidemiological Study of Vaccination and Sudden Infant Death
December 5, 2012
- PAFSC’s 1st Committee on New Drugs Recommends Orphan Drug Designation for 2 Products Including Kyowa Kirin’s Cinacalcet
December 4, 2012
- 3 Products Including Daiichi Sankyo’s Calblock Classified as Category I
December 4, 2012
- PAFSC’s 1st Committee Recommends Approval for Factor Xa Inhibitor Apixaban
December 3, 2012
- MHLW to Conduct Field Study for Japanese Version of “Compassionate Use” System
December 3, 2012
- Price Agreement Rates for JPWA, NPhA Member Companies Just 11% at End of September: Distribution Council
December 3, 2012
- Price Agreement Rate at 43.5% in September; Down 3.2 Points from 2 Years Ago: MHLW Survey
December 3, 2012
- 6 APIs Including Taiho’s Aloxi IV Infusion Bag Added to NHI Price List
December 3, 2012
- PAFSC’s 2nd Committee Recommends Approval for Allegra-Pseudoephedrine Combination Drug Dellegra
November 30, 2012
- Expert Subcommittee to Discuss New Targets for Generic Drugs at Next Meeting
November 30, 2012
- MHLW Safety Info. Calls for Caution on Pulmonary Hypertension Associated with Glivec
November 30, 2012
- FPMAJ Chairman Naito Nudges CSIMC to Discuss Perpetuation of Premiums, Abolishment of Special Price Cuts for Long-Listed Drugs
November 29, 2012
- Switch OTC Version of Ebastine Recommended for Approval
November 28, 2012
- BIKEN Exits New Flu Vaccine Development Project, MHLW to Invite Other Makers
November 26, 2012
- LDP Policy Statement Calls for Perpetuation of New Drug Premium, Promotion of Switch-OTC Drugs
November 26, 2012
- MHLW Approves Additional Indications for 3 APIs/5 Products, Including Botox
November 26, 2012
- Even Non-Welfare Beneficiaries Have No Obligation to Use of Generics: Health Minister Mitsui
November 22, 2012
- MHLW Set to Clarify Review Procedures for Companion Diagnostics
November 21, 2012
- Translational Research, Biobank Projects Require Drastic Revision: Project Screening
November 21, 2012
- PAFSC’s 2nd Committee to Review 7th Biopharmaceutical RA Drug on Nov. 29
November 20, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…